Aspire Biopharma Holdings (ASBP) Accounts Payables (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Accounts Payables for 6 consecutive years, with $972108.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accounts Payables fell 28.08% year-over-year to $972108.0 in Q2 2026; TTM through Jun 2026 was $972108.0, a 28.08% decrease from a year earlier, with the FY2025 full-year figure at $1.0 million, up 226.99% from the prior year.
• Accounts Payables was $972108.0 for Q2 2026 at Aspire Biopharma Holdings, up from $857925.0 in the prior quarter.
• Over five years, Accounts Payables peaked at $1.4 million in Q1 2025 and troughed at $19067.0 in Q1 2022.
• A 5-year average of $522914.5 and a median of $310219.0 in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables surged 66066.3% in 2022 and slumped 40.09% in 2026, its largest moves.
• Over 5 years, Accounts Payables stood at $180634.0 in 2022, then dropped by 15.85% to $152005.0 in 2023, then soared by 104.08% to $310219.0 in 2024, then jumped by 226.99% to $1.0 million in 2025, then retreated by 4.17% to $972108.0 in 2026.
• The last three Accounts Payables figures came in at $972108.0 (Q2 2026), $857925.0 (Q1 2026), and $1.0 million (Q4 2025), per Business Quant data.